RYALTRIS - (0.025MG/SPRAY;0.665MG/SPRAY ; SPRAY,METERED)

Generic Name	MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE	**Innovator**	Glenmark
Dosage	0.025MG/SPRAY;0.665MG/SPRAY ; SPRAY,METERED	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	Less Than 5	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	RYALTRIS is a combination of olopatadine, a histamine-1 (H1)receptor inhibitor, and mometasone furoate, a corticosteroid, indicated for the treatment of symptoms of seasonal allergic rhinitis in adult and pediatric patients 12 years of age and older.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.